GRI

In December 2025, the company closed an $8.0 million public offering. In January 2026, GRI Bio raised an additional $6.5 million through an At The Market offering and a 1-for-28 reverse stock split became effective. The U.S. Patent and Trademark Office issued a patent for a distinct class of proprietary compounds in January 2026. The stock experienced a surge after positive gene expression data for its IPF drug candidate was reported. In February 2026, GRI Bio reiterated its full-year 2025 financial results and highlighted key clinical and corporate achievements. In March 2026, despite reporting additional positive data from its Phase 2a study in IPF, the stock slumped by 20%. In April 2026, the company received a Notice of Allowance for a UAE Patent Application. The stock has experienced a significant decline over the past year, with a 96.28% drop between May 2, 2025, and April 30, 2026.